PF-Atlas › Clinical Trials › NCT02657473

Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis

tobramycin inhalation solution · Phase 2

Registry ID
NCT02657473
Phase
Phase 2
Status
Completed
Drug / intervention
tobramycin inhalation solution
Sponsor
Medical Center Alkmaar
Start
2016-08-13
Enrollment
58
Locations
6

About this trial

The purpose of this study is to evaluate the effect of tobramycin inhalation solution (TIS) once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint is a reduction of exacerbations of the disease during the treatment period. Next to this parameter the investigators expect to show a significant beneficial effect on lung function parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance.

View NCT02657473 on ClinicalTrials.gov →

Explore related

All tobramycin inhalation solution trialsAll IPF trials

Related trials

Tobramycin inhalation solution — NCT06106789
Medical disclaimer. This page summarizes public trial data for NCT02657473 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.